Armata Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
40.1%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$3.81next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
AP-SA02 Phase 3 Trial Initiation AnnuallyTarget: Initiation of Phase 3 clinical study in complicated S. aureus bacteremia
Unrestricted Cash and Cash Equivalents Quarterly4.8MTarget: Sufficient liquidity to fund operations through Phase 3 milestones
Grant and Award Revenue Quarterly800KTarget: Continued non-dilutive funding from MTEC/DoD for AP-SA02 program
Watch Items
- Innoviva Financial Support and Credit AgreementsTrigger: Maturity of existing credit agreements on June 1, 2027, or utilization of the $25 million secured term loanAction: Monitor debt restructuring, warrant exercises, or additional equity/debt financing from majority owner Innoviva
- FDA Regulatory Milestones for AP-SA02Trigger: FDA feedback or protocol finalization for the Phase 3 superiority study in complicated SABAction: Review clinical trial design, patient enrollment targets, and endpoint definitions
- Going Concern Explanatory ParagraphTrigger: Audit opinion recurring losses and negative operating cash flowsAction: Assess cash runway extensions, operational cost-cutting, or strategic partner funding
Research as of 20 Jun 2026